Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 24, 2024
Product Development
Clinical report: Sanofi data advances pair of autoimmune disease mechanisms
Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
BioCentury | Mar 28, 2024
Data Byte
Eight PDUFA dates on deck in April
J&J and Legend’s CAR T therapy could move into earlier lines; Day One could get its first marketed product
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Aug 19, 2023
Regulation
Aug. 18 Quick Takes: FDA approvals for Regeneron, Neurocrine
Plus: Priority review for full approval of Calliditas’ Tarpeyo and updates from Astellas-Iveric, Merck, Arch newco TFC
BioCentury | Jul 31, 2023
Data Byte
Over a dozen PDUFA dates on FDA’s August calendar
Decisions due next month include Sage’s depression therapy zuranolone and candidates for two ultra-rare diseases
BioCentury | Jan 21, 2022
Data Byte
State of the Huntington’s disease pipeline
Setbacks for HTT-targeting programs have put alternative therapeutic approaches out in front
BioCentury | Jan 8, 2022
Finance
Buysiders eye 2022 as the year of immuno-oncology’s next big act
High hopes for catalysts brewing for years have investors expecting a new era, and neurology may be on the upswing too
BioCentury | Dec 9, 2021
Finance
Dec. 8 Quick Takes: Germany’s Merck pours another €600M into M Ventures
Plus FDA panel rebuffs Reata’s bardoxolone and updates from Radius, OncoMyx, Neurocrine and Merck & Co.
BioCentury | Jun 4, 2020
Emerging Company Profile
Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round
The Dutch and Israeli company plans to take pridopidine into pivotal studies for Huntington’s, ALS
BioCentury | Feb 21, 2020
Product Development
Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit
Items per page:
1 - 10 of 115